Acadia Pharmaceuticals Inc. (ACAD) Q2 2009 Earnings Results

ACADIA PHARMACEUTICA Misses on EPS, Stock Down 3.34%

The earnings report indicates that ACADIA PHARMACEUTICA is facing difficulties, as reflected in the missed EPS target. The stock fell by 3.34% following the announcement, likely due to investor concerns over the lack of revenue data and no guidance for future performance. Management's defensive tone suggests ongoing challenges ahead.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.34	N/A	-1.19%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed concern over the current market conditions affecting performance. They are prioritizing cost management and operational improvements.

Management highlighted ongoing challenges in the current market environment.

They emphasized the need for continued focus on operational efficiency.

ACADIA PHARMACEUTICA Misses on EPS, Stock Down 3.34%

Key numbers

Management commentary

Acadia Pharmaceuticals Inc.

More earnings this week

ACADIA PHARMACEUTICA Misses on EPS, Stock Down 3.34%

Key numbers

Management commentary